Mesoblast Limited vs Silicon Motion Technology Corporation American Depositary Shares — how do they compare? Mesoblast Limited trades at $13.76 (market cap $1.83B), while Silicon Motion Technology Corporation American Depositary Shares trades at $218.54 (market cap $8.36B). The key difference: Silicon Motion Technology Corporation American Depositary Shares is far larger — about 4.6× Mesoblast Limited's market cap, and Silicon Motion Technology Corporation American Depositary Shares pays a 0.81% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Silicon Motion Technology Corporation American Depositary Shares for 0 Days on average.
| MESO | SIMO | |
|---|---|---|
Market Cap | $1.83B | $8.36B |
Volume | 259,445 | 663,682 |
Sector | Health | Technology |
52-Week High | $20.96 | $336.90 |
52-Week Low | $13.19 | $80.16 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $1.91B | $8.35B |
Dividend Yield | — | 0.81% |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
Silicon Motion (SIMO) trades at $246.63, down 0.13% on the day, with technical indicators showing neutral signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $2.43 versus $2.13, and revenue growth projected to reach $1.3B in 2026. Analyst sentiment remains overwhelmingly positive with 81% buy ratings and a consensus price target of $356.25, representing 44% upside potential from current levels.
The outlook for SIMO appears favorable given accelerating enterprise storage demand and AI infrastructure expansion. Key risks include semiconductor cycle volatility and competitive pressures in NAND controllers. With robust profitability metrics including 31.6% ROE and expanding margins, the stock offers growth exposure to the AI storage market, though investors should monitor execution on Q3 2026 earnings expectations of $3.3 EPS.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Silicon Motion Technology Corporation designs and develops NAND flash controllers for solid-state storage, with flagship SSD, eMMC, and UFS controller products, including its Ferri-branded automotive and industrial storage solutions, used by OEMs and NAND flash makers worldwide.
Read more on SIMO →